Drug Profile
CS 3006
Alternative Names: CS3006; MEK inhibitor - CStone PharmaceuticalsLatest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator CStone Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in China (PO)
- 28 Jul 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Australia (PO)
- 29 Oct 2018 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease) in China (PO) ) (NCT03736850)